var data={"title":"Ferrous sulfate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ferrous sulfate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6192?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ferrous-sulfate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ferrous sulfate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=ferrous-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ferrous sulfate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170907\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BProtected Pedia Iron [OTC];</li>\n      <li>Fer-In-Sol [OTC];</li>\n      <li>Fer-Iron [OTC] [DSC];</li>\n      <li>FeroSul [OTC];</li>\n      <li>Ferro-Bob [OTC];</li>\n      <li>FerrouSul [OTC];</li>\n      <li>Iron Supplement Childrens [OTC];</li>\n      <li>Slow Fe [OTC];</li>\n      <li>Slow Iron [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170908\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fer-In-Sol;</li>\n      <li>Ferodan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170948\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Iron Salt</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170912\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing. Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012). Dose expressed in terms of elemental iron; ferrous sulfate contains ~20% elemental iron; ferrous sulfate exsiccated (dried) contains ~30% elemental iron.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, prevention in areas where anemia prevalence is &ge;40% (off-label): </b>Oral: Menstruating women (non-pregnant females of reproductive potential): 30 to 60 mg daily for 3 consecutive months in a year (WHO 2016a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, treatment of iron deficiency:</b> Oral: 100 to 200 mg daily in 2 to 3 divided doses (Liu 2012; Stoltzfus 1998; WHO 2001). <b>Note:</b> Extended release tablets are intended for once daily use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (off-label use):</b> Oral: 65 mg (325 mg ferrous sulfate) twice daily in combination with vitamin C in patients with a ferritin level &le;75 mcg/L (AAN [Winkelman 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170929\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ferrous-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ferrous sulfate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Multiple concentrations of ferrous sulfate oral liquid exist; close attention must be paid to the concentration when ordering and administering ferrous sulfate; incorrect selection or substitution of one ferrous sulfate liquid for another without proper dosage volume adjustment may result in serious over- or underdosing. Dosage expressed in terms of elemental iron; ferrous sulfate contains ~20% elemental iron; ferrous sulfate exsiccated (dried) contains ~30% elemental iron:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Iron deficiency anemia, prevention: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;4 months (receiving human milk as only nutritional source or &gt;50% as source of nutrition without iron fortified food): 1 mg/kg/day (Baker 2010); <b>Note:</b> In healthy, term infants, AAP does not recommend routine additional supplementation of iron be considered until at least 4 to 6 months if breastfed (full or partial) (Baker 2010; Schanler 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, prevention in areas where anemia prevalence is &ge;40% (off-label; WHO 2016b):</b> Oral: <b>Note: </b>In malaria-endemic areas, iron supplementation in infants and children should be done in conjunction with public health measures to prevent, diagnose and treat malaria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months to Children &lt;2 years: 10 to 12.5 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 years to &lt;5 years: 30 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 5 to 12 years: 30 to 60 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescent menstruating females (non-pregnant females of reproductive potential): 30 to 60 mg daily for 3 consecutive months in a year</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iron deficiency anemia, treatment of iron deficiency:</b> Oral: 3 to 6 mg/kg/day in 3 divided doses (Carney 2010, Kliegman 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170913\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Lower doses (15 to 50 mg elemental iron/day) may have similar efficacy and less GI adverse events (eg, nausea, constipation) as compared to higher doses (eg, 150 mg elemental iron/day) (Rimon 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170889\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elixir, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FeroSul: 220 (44 Fe) MG/5ML (473 mL) [contains alcohol, usp, fd&amp;c yellow #6 (sunset yellow), propylene glycol, saccharin sodium, sodium benzoate; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 220 (44 Fe) MG/5ML (5 mL [DSC], 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Liquid, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 220 (44 Fe) MG/5ML (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BProtected Pedia Iron: 75 (15 Fe) MG/ML (50 mL) [alcohol free, gluten free; contains sodium metabisulfite; citrus flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fer-In-Sol: 75 (15 Fe) MG/ML (50 mL) [contains alcohol, usp, sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fer-Iron: 75 (15 Fe) MG/ML (50 mL [DSC]) [contains sodium metabisulfite; lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Iron Supplement Childrens: 75 (15 Fe) MG/ML (50 mL) [alcohol free, dye free, gluten free, lactose free; contains sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 (15 Fe) MG/ML (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 (60 Fe) MG/5ML (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ferro-Bob: 325 (65 Fe) MG</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 325 (65 Fe) MG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FerrouSul: 325 (65 Fe) MG [sodium free, starch free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 325 (65 Fe) MG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 324 (65 Fe) MG, 325 (65 Fe) MG</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Slow Fe: 160 (50 Fe) MG [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Slow Fe: 142 (45 Fe) MG [contains fd&amp;c blue #1 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Slow Iron: 160 (50 Fe) MG [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 140 (45 Fe) MG</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170874\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170892\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Do not chew or crush extended-release preparations; administer with water or juice on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170891\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b> Iron-deficiency anemia: </b>Prevention and treatment of iron-deficiency anemias</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25941798\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Restless legs syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170955\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Feosol may be confused with Fer-In-Sol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fer-In-Sol may be confused with Feosol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Slow FE may be confused with Slow-K</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Multiple concentrations of liquid iron preparations exist. Fer-In-Sol drops (manufactured by Mead Johnson) and a limited number of generic products are available at a concentration of 15 mg/mL. However, a suspension product, MyKidz Iron 10 drops, is available at a concentration of 15 mg/1.5 mL. Check concentration closely prior to dispensing. Prescriptions written in milliliters (mL) should be clarified.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170881\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Constipation, darkening of stools, epigastric pain, gastrointestinal irritation, nausea, stomach cramps, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dental discoloration (temporary; liquid preparations), diarrhea, heartburn</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Contact dermatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170895\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iron salts or any component of the formulation; hemochromatosis, hemolytic anemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170878\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the &ldquo;anemia of chronic disease&rdquo; is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral iron formulations: Immediate release oral iron products are preferred for treatment of iron deficiency anemia; enteric coated and slow/sustained release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299324\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170883\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8444&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Iron Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Iron Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Iron Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron salts under fed conditions, but coadministration with or 2 hours after an iron salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Iron Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron salts. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any iron-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Entacapone: Iron Salts may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Salts. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron salts. Therapy with oral iron salts should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Isomaltoside: May decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) iron isomaltoside with other oral iron salts. Therapy with oral iron salts should begin 5 days after the last dose of IV iron isomaltoside.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the absorption of Iron Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Iron Salts may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for levo-, nor-, oflox-, pefloxacin, or nalidixic acid) oral iron salts<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Iron Salts. Iron Salts may decrease the serum concentration of Trientine. Management: Trientine manufacturer recommends avoiding concurrent use with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used; however, separate administration by at least 2 hours.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170904\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789293\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Iron crosses the placenta and fetal stores are obtained from the mother (McArdle 2011). Iron requirements are increased in pregnant women compared to nonpregnant females (IOM 2001). All pregnant women should be tested for iron deficiency anemia and treated with supplemental iron if needed (ACOG 2008; CDC 1998). Untreated iron deficiency anemia during pregnancy may be associated with an increased risk of low birth weight, preterm delivery, and perinatal mortality, as well as postpartum depression in the mother and decreased mental functioning in the offspring (ACOG 2008; CDC 1998; IOM 2001). Treatment improves maternal hematologic status and neonatal birth weight (Haider 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6789296\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Iron is present in breast milk. The amount of iron in breast milk is generally not influenced by maternal iron status (IOM 1991). Breast milk has a higher concentration of bioavailable iron than cow's milk or goat's milk. Breast milk or iron-fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants up to 6 months (CDC 1998; IOM 2001). Maternal iron requirements are increased in breastfeeding women (IOM 2001). All postpartum women at risk of gestational anemia (regardless of breastfeeding status) may be given iron with or without folic acid for 6 to 12 weeks postpartum to reduce the risk of anemia (WHO 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170898\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ferrous sulfate contains ~20% elemental iron (ie, 325 mg ferrous sulfate is equivalent to 65 mg elemental iron); ferrous sulfate exsiccated (dried) contains ~30% elemental iron.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers, and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dietary reference intake (IOM 2001): Note:</b> Dosage expressed in terms of elemental iron; ferrous sulfate contains ~20% elemental iron; ferrous sulfate exsiccated (dried) contains ~30% elemental iron.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0 to 6 months: 0.27 mg daily (adequate intake)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">7 to 12 months: 11 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 to 3 years: 7 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">4 to 8 years: 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">9 to 13 years: 8 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">14 to 18 years: Males: 11 mg daily; Females: 15 mg daily; Pregnant females: 27 mg daily; Lactating females: 10 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">19 to 50 years: Males: 8 mg daily; Females: 18 mg daily; Pregnant females: 27 mg daily; Lactating females: 9 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;50 years: 8 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170887\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Iron deficient anemia:</i> Hemoglobin and hematocrit; consider additional tests such as RBC count, RBC indices, serum ferritin, transferrin saturation, total iron-binding capacity, serum iron concentration, and erythrocyte protoporphyrin concentration (CDC 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cancer and chemotherapy-induced anemia:</i> Serum iron, total iron-binding capacity, transferrin saturation, or ferritin levels (baseline and periodic) (Rizzo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>CKD associated anemia (patients not on dialysis):</i> To monitor response to iron therapy: Hemoglobin, serum ferritin, transferrin saturation (KDIGO 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170890\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum iron:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: 75 to 175 mcg/dL (SI: 13.4 to 31.3 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: 65 to 165 mcg/dL (SI: 11.6 to 29.5 micromole/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serum ferritin (Ineck 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: 15 to 200 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: 12 to 150 ng/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Total iron binding capacity: 230 to 430 mcg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transferrin: 204 to 360 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Percent transferrin saturation: 20% to 50%</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170877\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces iron, found in hemoglobin, myoglobin, and other enzymes; allows the transportation of oxygen via hemoglobin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170894\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hematologic response: Oral: ~3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Reticulocytosis: 5 to 10 days; hemoglobin increases within 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal serum iron stores, 10% of an oral dose is absorbed; this is increased to 20% to 30% in persons with inadequate iron stores. Food and achlorhydria will decrease absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: To transferrin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine, sweat, sloughing of the intestinal mucosa, and menses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170897\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (FeroSul Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 (44 Fe) mg/5 mL (473 mL): $5.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 (44 Fe) mg/5 mL (473 mL): $6.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Liquid</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">220 (44 Fe) mg/5 mL (473 mL): $5.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (BProtected Pedia Iron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 (15 Fe) mg/mL (50 mL): $8.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fer-In-Sol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 (15 Fe) mg/mL (50 mL): $10.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 (15 Fe) mg/mL (50 mL): $5.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 (60 Fe) mg/5 mL (5 mL): $2.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Ferrous Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 (45 Fe) mg (30): $5.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Slow Fe Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">142 (45 Fe) mg (60): $13.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">324 (65 Fe) mg (100): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 (65 Fe) mg (100): $43.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ferrous Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">325 (65 Fe) mg (100): $2.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170899\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aktiferrin (HU);</li>\n      <li>Brisofer (PH);</li>\n      <li>Conferon (HU);</li>\n      <li>Duroferon (FI, NO, SE);</li>\n      <li>Eribell (PY);</li>\n      <li>Femas (JP);</li>\n      <li>Feosol (PH);</li>\n      <li>Feospan (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Feospan Z (AE);</li>\n      <li>Feospan-Z (QA);</li>\n      <li>Fer-In-Sol (AR, BR, CL, CZ, GR, HK, KW, PE, SA, VE);</li>\n      <li>Ferglobin (PH);</li>\n      <li>Ferlea (AR);</li>\n      <li>Fero-Gradumet (BE, ES, LU, NL, PL);</li>\n      <li>Feroba (KR);</li>\n      <li>Feromin (QA);</li>\n      <li>Feromin Oral Drops (SA);</li>\n      <li>Ferro Duretter (DK);</li>\n      <li>Ferro-grad (IT);</li>\n      <li>Ferro-Gradumet (AE, AT, AU, BG, BH, CH, CY, EG, HU, ID, IL, IQ, IR, JO, KW, LB, LY, OM, PT, SA, SY, YE);</li>\n      <li>Ferro-Liquid (AU);</li>\n      <li>Ferrogamma (DE);</li>\n      <li>Ferrogard (JO);</li>\n      <li>Ferrograd (GB, IE, MT);</li>\n      <li>Ferrograd C (IE);</li>\n      <li>Ferrolent (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ferrophor (DE);</li>\n      <li>Ferroplex &rdquo;Era&rdquo; (DK);</li>\n      <li>Ferrostatin (JP);</li>\n      <li>Ferrosterol (UY);</li>\n      <li>Fersulph (LK);</li>\n      <li>Haemoprotect (DE);</li>\n      <li>Hemobion (MX);</li>\n      <li>Iberol Drops (LK);</li>\n      <li>Inshel (TW);</li>\n      <li>Kdiron (QA);</li>\n      <li>Kidiron (TH);</li>\n      <li>Liquifer (NL);</li>\n      <li>Microfer (GR);</li>\n      <li>Mol-Iron (CO);</li>\n      <li>Pediafer (LB);</li>\n      <li>Pharmafer (LB);</li>\n      <li>Plastufer (DE);</li>\n      <li>Plexafer (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Retafer (FI, HR, MY);</li>\n      <li>Slow-Fe (AE, BB, BH, BM, BS, BZ, CY, EG, GY, IQ, IR, JM, JO, KW, LB, LY, OM, SA, SR, SY, TT, YE);</li>\n      <li>Sorbifer (HU);</li>\n      <li>Tardyferon (AE, BH, CY, ES, FR, HU, IL, LU, QA);</li>\n      <li>Valdefer (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2008, 112(1):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/18591330/pubmed\" target=\"_blank\" id=\"18591330\">18591330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker RD, Greer FR; Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). <i>Pediatrics</i>. 2010;126(5):1040-1050.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/20923825/pubmed\" target=\"_blank\" id=\"20923825\">20923825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carney LN, Nepa A, Cohen SS, et al. Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed. In: Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. American Society of Parenteral and Enteral Nutrition. Silver Spring, MD: 2010; 440-441.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-3):1-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/9563847/pubmed\" target=\"_blank\" id=\"9563847\">9563847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guideline: Iron Supplementation in Postpartum Women. Geneva, Switzerland: World Health Organization (WHO); 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/27583315/pubmed\" target=\"_blank\" id=\"27583315\">27583315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haider BA, Olofin I, Wang M, et al, &quot;Anaemia, Prenatal Iron Use, and Risk of Adverse Pregnancy Outcomes: Systematic Review and Meta-analysis,&quot; <i>BMJ</i>, 2013, 346:f3443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/23794316/pubmed\" target=\"_blank\" id=\"23794316\">23794316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershko C and Camaschella C. How I treat unexplained refractory iron deficiency anemia. <i>Blood.</i> 2014;123(3):326-333. doi: 10.1182/blood-2013-10-512624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/24215034/pubmed\" target=\"_blank\" id=\"24215034\">24215034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ineck B, Mason BJ, Lyons W. Chapter 104. Anemias. <i>Pharmacotherapy: A Pathophysiologic Approach</i>. DiPiro JT, ed. New York, NY: McGraw-Hill Medical; 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>, Washington, DC: National Academy Press, 2001.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3(suppl):1-150. Available at http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(11):1258-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/2123218/pubmed\" target=\"_blank\" id=\"2123218\">2123218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(2):109-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/22157204/pubmed\" target=\"_blank\" id=\"22157204\">22157204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx JJM, &ldquo;Normal Iron Absorption and Decreased Red Cell Iron Uptake in the Aged,&rdquo; <i>Blood</i>, 1979, 53:204-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/760850/pubmed\" target=\"_blank\" id=\"760850\">760850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McArdle HJ, Lang C, Hayes H, et al, &quot;Role of the Placenta in Regulation of Fetal Iron Status,&quot; <i>Nutr Rev</i>, 2011, 69(Suppl 1):17-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/22043877/pubmed\" target=\"_blank\" id=\"22043877\">22043877</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rimon E, Kagansky N, Kagansky M, et al, &ldquo;Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians,&rdquo; <i>Am J Med</i>, 2005, 118(10):1142-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/16194646/pubmed\" target=\"_blank\" id=\"16194646\">16194646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20975064\"></a>Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schanler RJ, Feldman-Winter L, Landers S, et al. Concerns with early universal iron supplementation of breastfeeding infants. <i>Pediatrics</i>. 2011;127(4):e1097.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/21460097/pubmed\" target=\"_blank\" id=\"21460097\">21460097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    United Nations Children&rsquo;s Fund, United Nations University, World Health Organization (WHO). Iron Deficiency Anaemia. Assessment, Prevention, and Control. A guide for programme managers. 2001. http://www.who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;87(24):2585-2593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/27856776/pubmed\" target=\"_blank\" id=\"27856776\">27856776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Adult Women and Adolescent Girls</i>. Geneva<sub>, </sub>Switzerland: World Health Organization; 2016a. https://www.ncbi.nlm.nih.gov/books/NBK361888/.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/27195351/pubmed\" target=\"_blank\" id=\"27195351\">27195351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Infants and Children</i>. Geneva, Switzerland: World Health Organization; 2016b. https://www.ncbi.nlm.nih.gov/books/NBK362032/.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/27195348/pubmed\" target=\"_blank\" id=\"27195348\">27195348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ferrous-sulfate-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8444 Version 206.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170907\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170908\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F170948\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F170912\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F170929\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F170913\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170889\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F170874\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F170892\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F170891\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25941798\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F170955\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F170881\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170895\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F170878\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299324\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F170883\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F170904\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6789293\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6789296\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F170898\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F170887\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F170890\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F170877\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F170894\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F170897\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170899\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8444|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ferrous-sulfate-patient-drug-information\" class=\"drug drug_patient\">Ferrous sulfate: Patient drug information</a></li><li><a href=\"topic.htm?path=ferrous-sulfate-pediatric-drug-information\" class=\"drug drug_pediatric\">Ferrous sulfate: Pediatric drug information</a></li></ul></div></div>","javascript":null}